United Therapeutics (NASDAQ:UTHR) CEO Sells $1,698,360.00 in Stock

Key Points

• Martine Rothblatt, CEO of United Therapeutics, sold 4,000 shares at an average price of $424.59, totaling approximately $1.7 million, which represents a 96.85% decrease in her ownership of the stock.
• Despite a slight 0.1% dip in United Therapeutics' stock price, trading at $432.69, the company has shown growth with a quarterly revenue increase of 11.7% year-over-year.
• Analysts maintain a positive outlook with a consensus target price of $457.21, supported by several firms raising their price objectives for the stock recently.

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 4,000 shares of the stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $424.59, for a total transaction of $1,698,360.00. Following the sale, the chief executive officer owned 130 shares in the company, valued at approximately $55,196.70. This trade represents a 96.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

United Therapeutics Stock Down 0.1%

United Therapeutics stock traded down $0.65 during mid-day trading on Monday, reaching $432.69. 645,022 shares of the company's stock were exchanged, compared to its average volume of 594,711. The company has a market cap of $19.52 billion, a P/E ratio of 16.89, a P/E/G ratio of 4.72 and a beta of 0.66. United Therapeutics Corporation has a twelve month low of $266.98 and a twelve month high of $459.48. The company has a fifty day moving average of $385.69 and a 200-day moving average of $328.19.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). The business had revenue of $798.60 million for the quarter, compared to analyst estimates of $802.13 million. United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.United Therapeutics's quarterly revenue was up 11.7% compared to the same quarter last year. During the same quarter last year, the company earned $5.85 earnings per share. Equities research analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Institutional Investors Weigh In On United Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of UTHR. F m Investments LLC grew its position in United Therapeutics by 1.3% during the 2nd quarter. F m Investments LLC now owns 2,580 shares of the biotechnology company's stock worth $741,000 after purchasing an additional 33 shares during the last quarter. HB Wealth Management LLC grew its position in United Therapeutics by 2.9% during the 2nd quarter. HB Wealth Management LLC now owns 1,235 shares of the biotechnology company's stock worth $355,000 after purchasing an additional 35 shares during the last quarter. Hohimer Wealth Management LLC grew its position in United Therapeutics by 0.3% during the 1st quarter. Hohimer Wealth Management LLC now owns 12,651 shares of the biotechnology company's stock worth $3,900,000 after purchasing an additional 37 shares during the last quarter. WealthCollab LLC grew its position in United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock worth $30,000 after purchasing an additional 38 shares during the last quarter. Finally, Park Avenue Securities LLC grew its position in United Therapeutics by 1.7% during the 2nd quarter. Park Avenue Securities LLC now owns 2,353 shares of the biotechnology company's stock worth $676,000 after purchasing an additional 39 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on UTHR. Bank of America increased their target price on shares of United Therapeutics from $314.00 to $463.00 and gave the stock a "neutral" rating in a report on Tuesday, September 2nd. Weiss Ratings restated a "hold (c+)" rating on shares of United Therapeutics in a report on Wednesday, October 8th. Oppenheimer raised their price objective on shares of United Therapeutics from $510.00 to $575.00 and gave the company an "outperform" rating in a report on Friday, September 5th. JPMorgan Chase & Co. reduced their price objective on shares of United Therapeutics from $350.00 to $330.00 and set an "overweight" rating on the stock in a report on Tuesday, July 8th. Finally, Cantor Fitzgerald raised their price objective on shares of United Therapeutics from $405.00 to $525.00 and gave the company an "overweight" rating in a report on Wednesday, September 10th. Ten research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $457.21.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.